What it's for (Indications)
- Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.
- It serves as a maintenance therapy designed for the long-term management of chronic asthma, aiming to reduce the frequency and severity of asthma symptoms such as wheezing, shortness of breath, and chest tightness.
- It is crucial to understand that zafirlukast is not intended for the relief of acute bronchospasm during an asthma attack; for such episodes, a short-acting beta-agonist should be used as a rescue medication.
- Its primary role is to improve pulmonary function, decrease the reliance on rescue inhalers, and contribute to overall better asthma control as part of a comprehensive treatment plan.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of zafirlukast varies by age. For adults and adolescents 12 years of age and older, the prescribed dose is 20 mg taken orally twice daily. For pediatric patients aged 5 to 11 years, the recommended dosage is 10 mg taken orally twice daily. A critical aspect of zafirlukast administration is its timing relative to meals; the medication must be taken without food to ensure optimal absorption and bioavailability. Patients should be instructed to take zafirlukast at least 1 hour before or 2 hours after meals. Adherence to this specific dosing schedule and consistent daily administration are paramount for achieving and maintaining the therapeutic efficacy required for effective, long-term asthma management. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with zafirlukast therapy include headache, nausea, diarrhea, and abdominal pain.
- Patients may also experience pharyngitis, rhinitis, and general infections, particularly upper respiratory tract infections.
- Other frequently observed adverse events include myalgia (muscle pain) and arthralgia (joint pain).
- While less common, more serious adverse effects have been reported, necessitating vigilance.
- These encompass elevations in liver enzymes, which can occasionally progress to severe hepatic dysfunction, including hepatitis or cholestasis.
- Furthermore, neuropsychiatric events such as agitation, aggression, anxiety, depression, hallucinations, insomnia, irritability, restlessness, suicidal ideation, and tremor have been observed.
- Patients must be advised to report any new or worsening symptoms, especially concerning their mood, behavior, or liver health, to their healthcare provider without delay.
Serious Warnings
- Black Box Warning: **Serious Warnings: Neuropsychiatric Events and Hepatic Effects** While zafirlukast does not carry a formal FDA-mandated Black Box Warning, it is associated with significant and potentially serious adverse reactions that necessitate careful clinical consideration and patient monitoring. Patients receiving zafirlukast should be closely observed for the emergence or worsening of neuropsychiatric events, which have been reported in post-marketing surveillance. These events can include, but are not limited to, agitation, aggression, anxiety, depression, disorientation, hallucinations, insomnia, irritability, memory impairment, restlessness, suicidal thoughts and behavior (including completed suicide), tremor, and vivid dreams. Patients and caregivers should be promptly educated about these potential risks and instructed to report any changes in behavior or mood to their healthcare provider immediately. Additionally, zafirlukast has been associated with significant hepatic dysfunction, including symptomatic hepatitis, cholestasis, and elevations in liver enzymes, sometimes progressing to liver failure. Liver function tests should be considered prior to initiating therapy and monitored periodically during treatment, particularly if patients develop symptoms suggestive of liver injury (e.g., fatigue, nausea, vomiting, dark urine, jaundice, right upper quadrant pain). Discontinuation of zafirlukast may be necessary if clinically significant hepatic adverse effects occur. The potential benefits of zafirlukast must be carefully weighed against these serious risks.
- Zafirlukast is not indicated for the treatment of acute asthma exacerbations or the reversal of acute bronchospasm; patients should continue to use their prescribed short-acting inhaled beta-agonists for acute symptoms.
- Significant warnings associated with zafirlukast therapy include the potential for neuropsychiatric events.
- These can manifest as changes in mood or behavior, such as agitation, aggression, depression, sleep disturbances, and, in rare instances, suicidal thoughts or behaviors.
- Patients and caregivers must be educated on these potential changes and instructed to seek immediate medical attention if they occur.
- Hepatic dysfunction, including symptomatic hepatitis and elevated liver enzymes, has been reported, sometimes leading to severe liver injury.
- Liver function tests should be considered prior to initiating treatment and periodically thereafter, especially in patients with pre-existing hepatic impairment or those developing symptoms suggestive of liver damage.
- Eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy (Churg-Strauss syndrome) have been reported in patients receiving leukotriene receptor antagonists, including zafirlukast.
- Although causality is not definitively established, clinicians should remain alert to these manifestations.
How it Works (Mechanism of Action)
Zafirlukast is a potent and selective antagonist of the leukotriene CysLT1 receptor. Its mechanism of action involves competitively blocking the binding of cysteinyl leukotrienes, specifically leukotriene D4 (LTD4) and E4 (LTE4), to their respective receptors located in the human airway. These leukotrienes are potent inflammatory mediators synthesized from arachidonic acid and released from various cells, including mast cells, eosinophils, and macrophages. By inhibiting CysLT1 receptors, zafirlukast effectively counteracts the downstream effects of leukotrienes, which include bronchoconstriction, increased vascular permeability leading to airway edema, enhanced mucus secretion, and the recruitment of inflammatory cells into the airways. This action ultimately leads to a reduction in airway inflammation and smooth muscle contraction, resulting in improved pulmonary function and a significant decrease in asthma symptoms, thereby contributing to the long-term control and prophylaxis of chronic asthma.